Published: 18 March 2021
Author(s): Rafael Dal-Ré, Rita Banzi
Issue: May 2021
Section: Commentary

Amid an unprecedented surge of COVID-19 cases in the UK, with an increasing number due to a novel more infectious SARS-CoV-2 variant,[1] the UK regulatory agency (MHRA) granted emergency approval to the AstraZeneca COVID-19 vaccine on 30 December 2020. The target population includes adults and elderly. The posology consisting of two separate doses given 4-12 weeks apart. Almost simultaneously, the UK health authorities recommended a dose interval of 12 weeks for both COVID-19 authorized vaccines (Pfizer/BioNTech; AstraZeneca), due to the shortage of doses and to vaccinate the highest number of citizens.

Newsletters

Stay informed on our latest news!